MedTrace Logo

Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%

NCT05264558 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2023-11-13

No results posted yet for this study

Summary

The study aims to assess the impact of models of HCV care on HCV testing, treatment uptake and cure within Cairns. Point of care testing for HCV , with test and treat strategies will be offered within a primary care service.

Conditions

  • Hepatitis C

Interventions

DEVICE

Xpert HCV Viral load finger stick point of care test (Cepheid)

Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.

DRUG

Epclusa 400Mg-100Mg Tablet

Same day HCV test and treatment

OTHER

Standard of care

Clinical services will receive additional education and have the option of providing incentives to attendees of service.

Sponsors & Collaborators

  • Cairns Hinterland Health Hospital and Health Services

    collaborator UNKNOWN

  • The University of Queensland

    collaborator OTHER

  • Macfarlane Burnet Institute for Medical Research and Public Health Ltd

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2023-08-31
Completion
2023-09-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05264558 on ClinicalTrials.gov